Intraperitoneal Chemotherapy for Ovarian Cancer: Overview and Perspective
作者： Gautam Rao , Marta Crispens , Mace L. Rothenberg
关键词:
摘要: Intraperitoneal (IP) chemotherapy has theoretical, pharmacologic, and clinical advantages over intravenous (IV) in women with optimally debulked epithelial ovarian cancer confined to the abdominal cavity. Consistent, statistically significant improvements both progression-free overall survival have been demonstrated three large phase III trials conducted United States during past 10 years. Nevertheless, concerns IP drug distribution systemic absorption, technical challenges of catheter placement incidence catheter-related complications, relevance these studies limited adoption therapy cancer. Current interest evaluation molecularly targeted therapies should build on progress that made through use
sci-hub.se 参考文章(25)
Kelsen Dp, Lewis Jl, Alcock Nw, Casper Es, Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the iv route. Cancer treatment reports. ,vol. 67, pp. 235- ,(1983)
E. Andreopoulou, T. Chen, L. Liebes, J. Lu, S. Moore, E. Fusco, P. Liu, J. Curtin, H. Hochster, F. Muggia, Phase I/pharmacology study of intraperitoneal (IP) 3-5 day topotecan alone and with cisplatin:on day 1: potential for consolidation in ovarian cancer Journal of Clinical Oncology. ,vol. 23, pp. 5045- 5045 ,(2005) , 10.1200/JCO.2005.23.16_SUPPL.5045
DeVita Vt, Dedrick Rl, Myers Ce, Bungay Pm, Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer Cancer treatment reports. ,vol. 62, pp. 1- 11 ,(1978)
Maurie Markman, Brian N. Bundy, David S. Alberts, Jeffrey M. Fowler, Daniel L. Clark-Pearson, Linda F. Carson, Scott Wadler, Joshua Sickel, Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group Journal of Clinical Oncology. ,vol. 19, pp. 1001- 1007 ,(2001) , 10.1200/JCO.2001.19.4.1001
C HELM, L RANDALLWHITIS, R MARTINIII, D METZINGER, M GORDINIER, L PARKER, R EDWARDS, Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma. Gynecologic Oncology. ,vol. 105, pp. 90- 96 ,(2007) , 10.1016/J.YGYNO.2006.10.051
Carolyn Runowicz, Should patients with ovarian cancer receive intraperitoneal chemotherapy following initial cytoreductive surgery Nature Reviews Clinical Oncology. ,vol. 3, pp. 416- 417 ,(2006) , 10.1038/NCPONC0556
Mace L. Rothenberg, P.Y. Liu, Patricia S. Braly, Sharon P. Wilczynski, Edward V. Hannigan, Scott Wadler, Gavin Stuart, Caroline Jiang, Maurie Markman, David S. Alberts, Combined Intraperitoneal and Intravenous Chemotherapy for Women With Optimally Debulked Ovarian Cancer: Results From an Intergroup Phase II Trial Journal of Clinical Oncology. ,vol. 21, pp. 1313- 1319 ,(2003) , 10.1200/JCO.2003.07.031
STEPHEN B. HOWELL, Intraperitoneal Cisplatin with Systemic Thiosulfate Protection Annals of Internal Medicine. ,vol. 97, pp. 845- 851 ,(1982) , 10.7326/0003-4819-97-6-845
S. Makhija, M. Leitao, P. Sabbatini, N. Bellin, L. Almadrones, L. Leon, D.R. Spriggs, R. Barakat, Complications Associated with Intraperitoneal Chemotherapy Catheters Gynecologic Oncology. ,vol. 81, pp. 77- 81 ,(2001) , 10.1006/GYNO.2000.6108
Joan L. Walker, Deborah K. Armstrong, Helen Q. Huang, Jeffrey Fowler, Kenneth Webster, Robert A. Burger, Daniel Clarke-Pearson, Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group Study Gynecologic Oncology. ,vol. 100, pp. 27- 32 ,(2006) , 10.1016/J.YGYNO.2005.11.013